PIPELINE
In addition to its discovery-stage FMRP program, Opna’s lead clinical compound, OPN-2853, a bromo and extra terminal (BET) domain inhibitor, is currently in a Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The company also expects to initiate a Phase 2 study with OPN-7486, a colony stimulating factor 1 (CSF1) receptor inhibitor, in patients with histiocytosis, a white blood cell disorder, in the first half of 2023.
Program
Target
Hit identification
Lead optimization
Preclinical
Phase 1
Phase 2
Hit identification
Lead optimization
Preclinical
Phase 1
Phase 2
BET Inhibitor
OPN-2853 is a differentiated BET bromodomain inhibitor in Phase 2 clinical trials in combination with ruxolitinib for the treatment of myelofibrosis.
Hit identification
Lead optimization
Preclinical
Phase 1
Phase 2
Dual Inhibitor
of CSF1R and TRK
OPN-7486 inhibits recruitment of pro-tumorigenic TAMs and enables immune response to tumors by blocking the CSF1R/CSF1 interaction
Hit identification
Lead optimization
Preclinical
Phase 1
Phase 2
Dual Inhibitor
of EP300 and CREBBP
EP300 AND CREBBP OPN-6602, a dual inhibitor of EP300 and CBP, is a candidate therapy for cancers such as prostate cancer, leukemias and multiple myeloma.
Hit identification
Lead optimization
Preclinical
Phase 1
Phase 2
CD73 Inhibitor
Opna’s differentiated class of orally bioavailable, small molecule CD73 inhibitors, provide an immune-oncology opportunity in several tumor types.
Hit identification
Lead optimization
Preclinical
Phase 1
Phase 2
TEAD Inhibitor
TEAD inhibitors provide a compelling treatment strategy in cancers with dysregulation in the Hippo Pathway.